Document:

EX-4.20

 Exhibit 4.20 

2019 FREE SHARE PLAN 

REGULATION 
  

 
 TABLE OF CONTENTS 

 

							
	 1.
	 	 Definitions
	  	 	1	 
	 2.
	 	 Shares Covered by Regulation 2019
	  	 	3	 
	 3.
	 	 Administration of Regulation 2019
	  	 	4	 
	 4.
	 	 Limitations
	  	 	4	 
	 5.
	 	 Term of Regulation 2019
	  	 	5	 
	 6.
	 	 Free Shares Award
	  	 	    	 
	 7.
	 	 Criteria and Conditions of Award
	  	 	6	 
	 8.
	 	 Calendar for the Free Shares Award
	  	 	    	 
	 9.
	 	 Adjustments
	  	 	9	 
	 10.
	 	 Intervening Transactions
	  	 	9	 
	 11.
	 	 Amendment of Regulation 2019 – Management
	  	 	10	 
	 12.
	 	 Tax and Social Security Rules
	  	 	10	 
	 13.
	 	 Specific Restrictions and Information
	  	 	10	 
	 14.
	 	 Responsibility of the Company
	  	
 	
    	
 
	 15.
	 	 Applicable Law, Jurisdiction
	  	 	11	 

  
  

2019 FREE SHARE PLAN 

REGULATION 2019 
 Based on the
authorization granted by the combined general meeting on May 24, 2019 the Board of Directors of DBV Technologies (the “Company”) decided, at its meeting on July 1rst ,2019 in accordance with Articles L.225-197-1 to L.225-197-5 of the Commercial Code, to adopt a regulation (“2019 FREE
SHARE Regulation”) for the purpose of awarding free shares in the Company to Eligible Persons (as defined below), which bylaw will govern the awarding of free shares, and the terms and conditions of which are set out below.

  

	1.	 DEFINITIONS 

 

	(a)	 “Share” means a share of the Company; 

 

	(b)	 “Free Share Allocation” means the free share allocation on the terms and conditions set out in
Regulation 2019; 

  
 1 

	(c)	 “Shareholders’ Authorization” means the authorization to allocate shares free of charge
granted to the Board of Directors by the shareholders of the Company at the extraordinary combined general meeting on May 24, 2019; 

  

	(d)	 “Beneficiary” means an Eligible Person to whom at least one Share has been allocated free of
charge in accordance with Regulation 2019; 

  

	(e)	 “Change of Control” means the completion of any transaction that has the effect of bringing
about a change in the Control of the Company. The term “Control” has the meaning given to it in Article L.233-3 of the Commercial Code; 

 

	(f)	 “Award Date” means the date on which the Board of Directors grants the Free Share Allocation
and constitutes the date on which the Acquisition Period commences; 

  

	(g)	 “Eligible Person” means an officer (President, director general, or deputy director general of
the Company) or employee of the Company or an Affiliate Company who meets the conditions set out in Articles L.225-197-1 and
L.225-197-2 of the Commercial Code and satisfies the conditions and criteria for the award established by the Board of Directors in its decision of May 24, 2019 and
set out in Article 7 of Regulation 2019; 

  

	(h)	 “Manager” means the Board of Directors of the Company that administers Regulation 2019
in accordance with Article 3 of Regulation 2019; 

  

	(i)	 “Disability” means a disability on the part of the Beneficiary that corresponds to
classification in the second or third category provided in Article L.341-4 of the Social Security Code; 

  

	(j)	 “Performance condition” means conditions determined by the Board of Directors referred to in
Article 7 of Regulation 2019. 

  

	(k)	 “Vesting Period” means the longer of (i) the two (2) years period from the Grant
Date and (ii) the period when the Performance Condition is met. 

  
 2 

	(J)	 “Regulation 2019” means this 2019 Free Share Plan as adopted by the Manager on May 24,
2019. 

  

	(k)	 “Employee” means a natural person who is employed by the Company (or any Affiliated
Company) and is subject to the power of control and direction of the employer entity in the performance and conduct of the work to be carried out; 

  

	(l)	 “Company” means DBV Technologies, a limited company incorporated under French law;

  

	(m)	 “Affiliated Company” means a company that meets the criteria set out in Article L.225-197-2 of the Commercial Code: 

  

	 	•	 	 companies of which at least ten percent (10%) of the capital or voting rights are held, directly or
indirectly, by the Company; 

  

	 	•	 	 companies that hold, directly or indirectly, at least ten percent (10%) of the capital or voting rights of
the Company; and 

  

	 	•	 	 companies of which at least fifty percent (50%) of the capital or voting rights are held, directly or
indirectly, by a company that itself holds, directly or indirectly, at least fifty percent (50%) of the capital or voting rights of the Company. 

  

	2.	 SHARES COVERED BY REGULATION 2019 

All Free shares plan based on the authorization granted by the combined general meeting on May 24, 2019 to the Board of Directors of DBV Technologies.

 The total number of Free shares according with the Shareholder’s authorization shall not exceed 2.0% of the share capital on the date of
May 24, 2019, Meeting (i.e. 723,155 shares). 

  
 3 

	3.	 ADMINISTRATION OF REGULATION 2019 

 

	 	(a)	 Administration 

Regulation 2019 will be administered by the Manager. 
  

	 	(b)	 Powers of the Manager 

Within the limits of the Commercial Code, the Shareholders’ Authorization and Regulation 2019, the Manager will have discretion to: 

 

	 	i.	 determine the Eligible Persons to whom Shares will be allocated free of charge and decide the number of bonus
Shares to be awarded to each of them; 

  

	 	ii.	 determine the terms and conditions of any Free Share Allocation; 

 

	 	iii.	 analyze and interpret the terms of Regulation 2019; 

 

	 	iv.	 decide to change or cancel any rule in Regulation 2019, within the limits prescribed by law;

  

	 	v.	 make any necessary or advisable decision in the course of executing Regulation 2019. 

 

	 	(c)	 Effects of Decisions of the Manager 

The decisions and interpretations of the Manager are final and binding on all Beneficiaries. 

 

	4.	 LIMITATIONS 

 

	(a)	 The Shares allocated free of charge are governed by Articles L.225-197-1 to L.225-197-5 of the Commercial Code. They do not in any way constitute a component of the contract of
employment or office or compensation of the Beneficiary. 

  
 4 

 Neither Regulation 2019 nor any Share allocated free of charge confers a right on the Beneficiary to remain
in employment in the Company or an Affiliated Company, or in office in the Company. Moreover, they do not in any event limit the right that the Beneficiary, the Company, or an Affiliated Company, as the case may be, may have to
terminate such employment or office in any circumstance, with or without cause. 
  

	(b)	 In accordance with Article
L.225-197-1 of the Commercial Code, no Share may be allocated free of charge to an Eligible Person who, at the time of allocation the Share, directly holds more than 10%
of the capital of the Company, or for whom the effect of the award would be to increase his/her participation to more than 10% of the capital of the Company. 

 

	5.	 TERM OF REGULATION 2019 

Relying on the authorization and powers granted to it by the General Shareholders’ Meeting on May 24, 2019, the Board of Directors, in its
decision dated July 31, 2019 decided to adopt Regulation 2019, which came into effect on July, 2019. Unless it is terminated early in accordance with the provisions of Article 11, the 2019 Free Share Plan Rules shall remain in force until the
expiration of the Vesting Period of the last free Share granted. 
  

	6.	 BONUS SHARE AWARD 

 

	 	(a)	 Decision to award 

The Manager will decide during Board of Directors meetings to allocate free shares to the new DBV Technologies S.A.’s employees according a fixed ratio.

  

	 	(b)	 Award of Shares and Acceptance by Beneficiaries 

Each Eligible Person will be informed of the Free Share Allocation by a notification letter setting out, in particular, (i) the number of Shares allocated
free of charge to him/her, (ii) the term of the Acquisition Period, (iii) the term of the Retention Period, (iv) the conditions and criteria to be met in order for the award to become definitive at the end of the Acquisition Period,
and (v) any obligation imposed on him/her. A copy of Regulation 2019 will be attached to the notification letter. A sample notification letter is set out in an Appendix to Regulation 2019. 

The notification letter will be sent to the Beneficiary by registered mail with acknowledgement of receipt or delivered by hand to the Beneficiary by the
Manager or by any duly authorized person, and the Beneficiary will acknowledge receipt. 
 In the event that the Beneficiary would like to take up the Free
Share Allocation, he/she must make his/her acceptance known to the Company by sending the second copy of the notification 

  
 5 

 
of the Free Share Allocation to the Company, addressed to the Manager, by registered mail with acknowledgement of receipt or by hand, signed by him/her under the notation “Good for
acceptance,” within thirty (30) days of receipt of the notification of the Free Share Allocation. 
 Acceptance of Regulation 2019 by a
Beneficiary constitutes acceptance of all of its terms. 
  

	7.	 CRITERIA AND CONDITIONS OF AWARD 

The allocation of the Shares will take place only at the end of a Vesting Period and subject to the fulfillment of a double condition of presence of the
Beneficiary and overall performance, in accordance with the objectives determined by the Board of Directors at the time of its decision of July 31, 2019 and which were brought to the attention of the Beneficiaries by individual letters: 

 

	 	(a)	 Vesting Period and Performance Condition 

The final allocation of the free shares will not take place until the later of the following two dates: 

(i) expiry of a vesting period of 2 years from their initial grant; or 

(ii) BLA approval of Viaskin Peanut by the U.S. Food and Drug Administration (U.S. FDA) (Performance Condition). 

In accordance with Article L.225-197-3 of the French Commercial Code, the
rights resulting from the Free Grant of Shares are non-transferable and non-assignable by any means whatsoever until the end of the Vesting Period (except for specific
provisions in the event of the Beneficiary’s death, see below). 
  

	 	(b)	 Presence condition 

The Beneficiary must retain the status of Eligible during the entire Vesting Period. 

The definitive allocation is also subject to a condition of presence assessed according to the terms and conditions specified below. 

To be Eligible, the beneficiaries must be linked, during the entire Vesting Period, to the Company or an Affiliated Company by a corporate mandate
and/or an employment contract. 
 Accordingly, in the event of resignation, voluntary or involuntary retirement, termination of the Beneficiary’s
contract of employment by mutual agreement with the company concerned, dismissal, removal, or non-renewal of the Beneficiary’s office, during the Acquisition Period, for any cause
whatsoever, the Beneficiary would, unless otherwise first decided by the Manager, lose all rights to the Free Share Allocation and could make no claim for compensation in that regard. 

  
 6 

	 	•	 	 Dismissal of the Beneficiary and/or removal and/or non-renewal of the
Beneficiary’s offices during the Acquisition Period: 

  

	 	•	 	 If the Beneficiary has only a contract of employment, the loss of the right to the
Free Share Allocation will take place on the date of receipt (or first presentation) of the letter of notification of dismissal, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by the
beneficiary of his/her dismissal and/or the reasons for the dismissal, and (iii) any judicial decision setting aside the dismissal. 

  

	 	•	 	 If the Beneficiary has only an office, the loss of the right to the Free Share Allocation will take place
on the date of the meeting of the corporate body at which the removal was decided or the Beneficiary was replaced as the office holder, if the beneficiary is a member of it, and if the Beneficiary is not a member of it, as of the date on which
notice of the decision is received by the Beneficiary, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by the beneficiary of his/her removal and/or the reasons for the removal, and
(iii) any judicial decision setting aside the removal. 

  

	 	•	 	 If the Beneficiary has both a contract of employment and an office and, in the event of
the simultaneous or successive loss of both positions, the loss of the right to the Free Share Allocation will take place on the date of receipt of the latter of the two notices referred to in the two preceding paragraphs. 

 

	 	•	 	 Resignation during the Acquisition Period: 

In the event of the resignation of the Beneficiary from his/her position as an employee, if the Beneficiary is an employee only, or as an officer, if the
Beneficiary is an officer only, or in the event of simultaneous or successive resignation from his/her position as an employee and as an officer, in the event that the Beneficiary holds both positions at the same time, the loss of the right to the
Free Share Allocation will take place: 
  

	 	•	 	 if the Beneficiary is only an employee or an officer, on the date of receipt by the Company of the
Beneficiary’s letter of resignation or on the date on which it is delivered by hand to an authorized representative of the Company that employs him/her; and 

 

	 	•	 	 if the Beneficiary holds positions as both an employee and an officer, the date of receipt by the
Company of the first of the letters of resignation, or the date on which it is delivered by hand to an authorized representative of the Company that employs him/her. 

  
 7 

 notwithstanding any notice requirement, whether or not it has been given. 

 

	 	•	 	 Mutual agreement between the Beneficiary and the company that employs him/her during the Acquisition
Period: 

 In the event of termination of the contract of employment by mutual agreement between the Beneficiary and the
company that employs him/her (including in the case of contractual termination) if the Beneficiary is only an employee, or in the case of termination of the contract of employment by mutual agreement between the Beneficiary and the
company that employs him/her and the simultaneous or successive resignation or removal from his/her office, in the event that the Beneficiary holds both positions at the same time, the Beneficiary would lose his/her right to the Free Share
Allocation on the first date on which the agreement terminating the Beneficiary’s position as an employee is signed (or on which the agreement relating to the contractual termination is made), or the date of receipt of the notification of
removal from office or the date of resignation from office. 
  

	 	•	 	 Retirement of the Beneficiary during the Acquisition Period; 

In the event that the Beneficiary retires during the Acquisition Period, the Beneficiary will lose his/her right to the Free Share Allocation on the date of
retirement. 
 However, by exception to the foregoing: 
  

	(i)	 in the event of the involuntary retirement of the Beneficiary at the initiative of the company that
employs him/her during the Acquisition Period, in accordance with the applicable statutory and regulatory requirements, the Beneficiary will retain his/her right to the Free Share Allocation, on the condition that he/she adheres to the Acquisition
Period; 

  

	(ii)	 in the event of the death of the Beneficiary during the Acquisition Period, his/her heirs may request the Free
Share Allocation within six (6) months of the death; 

  

	(iii)	 in the event of disability, the Beneficiary may request that the Shares be awarded within six (6) months
of the event that resulted in the disability. 

 It is specified that during the Acquisition Period, the Beneficiaries are not the owners
of the Shares and have no shareholder’s rights. In particular, they do not have the right to dividends, the right to vote, or the right to the information communicated to shareholders attached to the Shares. 

  
 8 

	 	(b)	 Delivery of the Shares 

At the end of the Acquisition Period, the Company will, on the condition that the Beneficiary has adhered to the conditions and criteria of acquisition
set out in Article 7 above, transfer to the Beneficiary the number of Shares decided by the Board of Directors. 
 The shares awarded will immediately be
treated in the same manner as the existing shares and will carry immediate dividend rights. 
  

	 	(c)	 No Share Retention Period 

The Beneficiary shall be a shareholder as soon as the Shares are definitively allocated. 

As soon as they have been definitively allocated, the shares allocated free of charge may be freely transferred by the Beneficiary, subject to the regulations
applicable to companies whose securities are admitted to trading on a regulated market (see in particular Article 13). 
  

	9.	 ADJUSTMENTS 

The Manager will be the only person with authority to decide, where applicable, the conditions on which the number of bonus Shares awarded will be adjusted in
the event of transactions involving the capital of the Company in order to preserve the rights of the Beneficiaries of the said Free Share Allocations. 
  

	10.	 INTERVENING TRANSACTIONS 

 

	(a)	 Take over of control 

In the event of a takeover of control and by derogation from the provisions of Articles 7 and 8 of this regulation, the beneficiaries will remain eligible for
the allocation at the end of the vesting period, even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the takeover and the last day of the vesting period. In this specific case, the shares
will vest with no requirement to wait for the plan’s performance criteria to be met. 
  

	(b)	 Exchange of Shares 

In the event of an exchange of shares resulting from a merger or split carried out in accordance with the regulations in force during the acquisition period,
the provisions of this Article and, in particular, the above-mentioned periods, for the times remaining to run on the date of the exchange, will continue to be applicable to the rights to the award and the shares received in exchange. 

  
 9 

	11.	 AMENDMENT OF REGULATION 2019 - MANAGEMENT 

 

	 	(a)	 Amendment 

The Manager may, at any time, amend the provisions of, suspend, or terminate Regulation 2019, on the condition that it is done in compliance with the law. 

 

	 	(b)	 Consequences of Amendment or Cancellation 

No amendment, alteration, suspension, or cancellation of Regulation 2019 may reduce the rights of a Beneficiary without his/her agreement, unless such
amendment results from a legislative or regulatory provision that has newly come into force or from any other provision that has executory effect and is mandatory for the Company or an Affiliated Company. 

 

	 	(c)	 Management 

The management of Regulation 2019 is assigned to the Manager. However, the Manager reserves the ability to assign the management of Regulation 2019 to any
financial institution. The Manager will inform the Beneficiaries by registered letter with acknowledgement of receipt or delivery by hand specifying the name and contact information of the financial institution chosen by the Manager to handle the
management of Regulation 2019. 
  

	12.	 TAX AND SOCIAL SECURITY RULES 

The Beneficiary will bear the cost of all taxes and mandatory deductions for which he/she is responsible under the tax regulations in force on the date on
which the taxes or deductions become payable. 
 The Beneficiary is invited to obtain advice about his/her own personal tax situation, in particular in
order to be aware of the tax and social security treatment that will apply to him/her, and the Beneficiary declares that he/she is not in any way relying on any tax or social security advice given by the Company. 

 

	13.	 SPECIFIC RESTRICTIONS AND INFORMATION 

Any person who holds shares of a company must, in general, abstain from transferring them, acquiring new shares, or giving advice concerning those shares if
he/she is in possession of information that could have a significant influence on the market price of the company that has not been made public. Persons who violate those rules may be subject to penal and financial sanctions. Those rules
apply to Eligible Persons who receive Shares. 
 We invite you to refer to the Code of Ethics adopted by the Company that is online on the Intranet.

  
 10 

 Moreover, in accordance with Article
L.225-197-1 I of the Commercial Code, the Shares may not be assigned or transferred after the expiration of the Retention Period: 

 

	 	•	 	 within ten (10) trading sessions preceding and three (3) trading sessions following the date on which
the consolidated accounts or, if none, the annual accounts are made public; 

  

	 	•	 	 within the time between the date on which the corporate bodies of the Company have knowledge of
information that, if it were made public, could have a significant impact on the market price of the Company’s shares, and the date ten (10) trading sessions before the date on which the information is made public.

 A calendar of publications is distributed annually and is accessible online on the Intranet. 

In accordance with the provisions of Article L.621-18-2 of the Monetary and
Financial Code, the transfer of shares by an officer or any person who has, within the Company, (i) the power to make management decisions concerning the Company’s activities and strategy, and (ii) regular access to
privileged information concerning the Company directly or indirectly requires that information be provided to the Autorité des Marchés Financiers [financial markets authority], with a copy to the Company, within the time
allowed by the regulations in force. 
  

	15.	 LIABILITY OF THE COMPANY 

The Company and its Affiliated Companies may not, in any way, be held liable if, for any reason whatsoever not attributable to the Company or its
Affiliated Companies, a Beneficiary was not able to acquire the Shares awarded to him/her. 
  

	16.	 APPLICABLE LAW, JURISDICTION 

Regulation 2019 is governed by French law and in particular by the provisions of Articles
L.225-197-1 et seq. of the Commercial Code. 
 Any dispute relating
to Regulation 2019 will be within the exclusive jurisdiction of the court of competent jurisdiction subject to the jurisdiction of the court of appeal in the place in which the head office of the Company is located. 

The Free Share Allocation under Regulation 2019 authorizes the Society, at any time, to ask the Beneficiary to comply with any legislative and regulatory
provision governing the Shares. 
 *        *        * 

* 

  
 11 

 APPENDIX 

SAMPLE NOTIFICATION LETTER CONCERNING DBV TECHNOLOGIES FREE 

SHARE ALLOCATION 

Montrouge, [date] 

        [Name of Beneficiary] 

Dear Sir/Madam: 
 We are pleased to inform you that the Board of
Directors of the Company has decided to allocate free shares of the Company to you in accordance with the provisions of the regulation governing the free share plan, a copy of which is attached in an Appendix
(“Regulation 2019”). 
 The terms that are not defined in this letter and that are capitalized have the meaning assigned to them in
Regulation 2019. 
 These free Shares have been awarded under the provisions of Articles L.225-197-1 to L.225-197-5 of the Commercial Code. 

  
 12 

 Under the decision of the Board of Directors, you were awarded
[                    ] ([                ]) free shares of the
Company, on [                    ], on the terms set out below. 
  

	1.	 Acquisition Period and conditions 

The definitive allocation of the free shares will only occur at the later of the following two dates, subject to the presence requirement set
out below: 
 (i) expiry of the current vesting period ( 2 years) as from their initial allocation; and 

(ii) approval of Viaskin Peanut by the US Food and Drug Administration (US FDA) (performance condition). 

 

	2.	 Conditions and criteria of allocation 

The Free Share Allocation assumes that during the Acquisition Period referred to above, you will meet the following conditions and criteria: 

You must, throughout the Acquisition Period, have a relationship with the Company or an Affiliated Company under an office and/or a contract of
employment. 
 In the event of resignation, voluntary or involuntary retirement, termination of the contract of employment by mutual agreement,
dismissal, removal, or termination of the office, during the Acquisition Period, for any reason whatsoever, you will lose all right to the Free Share Allocation and may claim no compensation in that regard. 

In the event of resignation, the loss of the right to the Free Share Allocation will occur on the date of receipt by the Company or the Affiliated
Company concerned of your letter of resignation or on the date of delivery by hand of the letter to an authorized representative of the company that employs you, notwithstanding any notice requirement, whether or not it has been given. 

In the event of dismissal or removal, the loss of the right to the Free Share Allocation will occur on the date of receipt (or first presentation) of the
letter of notification of dismissal or removal, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by you of your dismissal and/or the reasons for the dismissal, and (iii) any judicial
decision setting aside the dismissal. 
 However, by exception to the foregoing, 
  

	(i)	 in the event of retirement during the Acquisition Period, you will retain your right to the Free Share
Allocation; 

  

	(ii)	 in the event of death during the Acquisition Period, your heirs may request the Free Share Allocation within
six (6) months of the date of your death. 

  

	(iii)	 in the event disability during the Acquisition Period, you may request the Free Share Allocation within six
(6) months of the date of your disability. 

  

	(iv)	 In the event of a takeover of control within the meaning of Article L.
233-3 of the French Commercial Code of DBV Technologies by any person acting alone or in concert with other persons, the beneficiaries will remain eligible for the allocation at the end of the vesting period,
even if their employment contract and/or corporate mandate is terminated, 

  
 13 

	 	
for any reason, between the date of the takeover and the last day of the vesting period. In this specific case, the shares will vest with no requirement to wait for the plan’s performance
criteria to be met. 

  

	3.	 Retention Period 

No retention period, the Shares will become available and may, in particular, be freely transferred (subject to the abstention periods referred to in
Regulation 2019). 
 Your acceptance of the Free Share Allocation on the terms set out above constitutes acceptance of the terms of Bylaw 2019. 

In the event that you accept the Free Share Allocation, we would appreciate it if you would sign two copies of this notification of Free Share Allocation and
keep one copy and return the other to the Company by registered letter or delivered by hand in a period of 30 days from the receipt of this letter. Otherwise, the award will be void. 

 

	
	Sincerely yours,
	
	Daniel Tassé

  

	
	Good for acceptance
	
	[Name of Beneficiary]
	
	Encl.: Regulation 2019

  
 14 

 2019-2 FREE SHARE PLAN 

REGULATION 
  

 
 TABLE OF CONTENTS  

 

							
	 1.
	 	 Definitions
	  	 	15	 
	 2.
	 	 Shares Covered by Regulation 2019-2
	  	 	17	 
	 3.
	 	 Administration of Regulation 2019-2
	  	 	18	 
	 4.
	 	 Limitations
	  	 	19	 
	 5.
	 	 Term of Regulation 2019-2
	  	 	19	 
	 6.
	 	 Free Shares Award
	  	 	19	 
	 7.
	 	 Criteria and Conditions of Award
	  	 	20	 
	 8.
	 	 Calendar for the Free Shares Award
	  	 	    	 
	 9.
	 	 Adjustments
	  	 	22	 
	 10.
	 	 Intervening Transactions
	  	 	22	 
	 11.
	 	 Amendment of Regulation 2019-2 –
Management
	  	 	23	 
	 12.
	 	 Tax and Social Security Rules
	  	 	23	 
	 13.
	 	 Specific Restrictions and Information
	  	 	23	 
	 14.
	 	 Responsibility of the Company
	  	 	24	 
	 15.
	 	 Applicable Law, Jurisdiction
	  	 	24	 

  
  

2019 FREE SHARE PLAN 

REGULATION 2019-2 

Based on the authorization granted by the combined general meeting on May 24, 2019 the Board of Directors of DBV Technologies (the
“Company”) decided, at its meeting on December 19, 2019 in accordance with Articles L.225-197-1 to L.225-197-5 of the Commercial Code, to adopt a regulation (“2019-2 FREE SHARE Regulation”) for the purpose of awarding free shares in the
Company to Eligible Persons (as defined below), which bylaw will govern the awarding of free shares, and the terms and conditions of which are set out below. 
  

	1.	 DEFINITIONS 

 

	(a)	 “Share” means a share of the Company; 

 

	(b)	 “Free Share Allocation” means the free share allocation on the terms and conditions set out in
Regulation 2019-2; 

  
 15 

	(c)	 “Shareholders’ Authorization” means the authorization to allocate shares free of charge
granted to the Board of Directors by the shareholders of the Company at the extraordinary combined general meeting on May 24, 2019; 

  

	(d)	 “Beneficiary” means an Eligible Person to whom at least one Share has been allocated free of
charge in accordance with Regulation 2019-2; 

  

	(e)	 “Change of Control” means the completion of any transaction that has the effect of bringing
about a change in the Control of the Company. The term “Control” has the meaning given to it in Article L.233-3 of the Commercial Code; 

 

	(f)	 “Award Date” means the date on which the Board of Directors grants the Free Share Allocation
and constitutes the date on which the Acquisition Period commences; 

  

	(g)	 “Eligible Person” means any person who meets the following two cumulative conditions:

  

	 	•	 	 be an employee under an indeterminate or fixed-term contract with DBV Technologies SA; and 

 

	 	•	 	 provide proof of at least three months’ seniority with DBV Technologies SA. 

 

	(h)	 “Manager” means the Board of Directors of the Company that administers Regulation 2019-2 in accordance with Article 3 of Regulation 2019-2; 

  

	(i)	 “Disability” means a disability on the part of the Beneficiary that corresponds to
classification in the second or third category provided in Article L.341-4 of the Social Security Code; 

  

	(j)	 “Vesting Condition” means the presence condition provided for in Article 7 below to which the
acquisition by the Beneficiary of an irrevocable right of ownership of all or part of the Shares allocated to him/her is subject; 

  

	(k)	 “Vesting Period” means the period of two (2) years from December 19, 2019, in
accordance with the decision of the Combined Shareholders’ Meeting of May 24, 2019; 

  
 16 

	(J)	 “Regulation 2019-2” means this 2019-2 Free Share Plan as adopted by the Manager on December 19, 2019. 

  

	(k)	 “Employee” means a natural person who is employed by the Company (or any Affiliated
Company) and is subject to the power of control and direction of the employer entity in the performance and conduct of the work to be carried out; 

  

	(l)	 “Company” means DBV Technologies, a limited company incorporated under French law;

  

	(m)	 “Affiliated Company” means a company that meets the criteria set out in Article L.225-197-2 of the Commercial Code: 

  

	 	•	 	 companies of which at least ten percent (10%) of the capital or voting rights are held, directly or
indirectly, by the Company; 

  

	 	•	 	 companies that hold, directly or indirectly, at least ten percent (10%) of the capital or voting rights of
the Company; and 

  

	 	•	 	 companies of which at least fifty percent (50%) of the capital or voting rights are held, directly or
indirectly, by a company that itself holds, directly or indirectly, at least fifty percent (50%) of the capital or voting rights of the Company. 

  

	2.	 SHARES COVERED BY REGULATION 2019-2

 All Free shares decided by the Board of Directors on December 19, 2019 on the basis of the authorization granted by the
Company’s Combined General Meeting of May 24, 2019, is governed by these regulations. 
 It is specified that the number of free shares that may be
allocated pursuant to the aforementioned authorization is limited to 659,405 shares, taking into account the shares already allocated by virtue of this authorization.

  
 17 

	3.	 ADMINISTRATION OF REGULATION 2019-2

  

	 	(a)	 Administration 

Regulation 2019-2 will be administered by the Manager. 

 

	 	(b)	 Powers of the Manager 

Within the limits of the Commercial Code, the Shareholders’ Authorization and Regulation 2019-2, the Manager will
have discretion to: 
  

	 	i.	 determine the Eligible Persons to whom Shares will be allocated free of charge and decide the number of bonus
Shares to be awarded to each of them; 

  

	 	ii.	 determine the terms and conditions of any Free Share Allocation; 

 

	 	iii.	 analyze and interpret the terms of Regulation 2019-2;

  

	 	iv.	 decide to change or cancel any rule in Regulation 2019-2, within the
limits prescribed by law; 

  

	 	v.	 make any necessary or advisable decision in the course of executing Regulation
2019-2. 

  

	 	(c)	 Effects of Decisions of the Manager 

The decisions and interpretations of the Manager are final and binding on all Beneficiaries. 

  
 18 

	4.	 LIMITATIONS 

 

	(a)	 The Shares allocated free of charge are governed by Articles L.225-197-1 to L.225-197-5 of the Commercial Code. They do not in any way constitute a component of the contract of
employment or office or compensation of the Beneficiary. 

 Neither Regulation 2019-2 nor any
Share allocated free of charge confers a right on the Beneficiary to remain in employment in the Company or an Affiliated Company, or in office in the Company. Moreover, they do not in any event limit the right that the Beneficiary,
the Company, or an Affiliated Company, as the case may be, may have to terminate such employment or office in any circumstance, with or without cause. 
  

	(b)	 In accordance with Article
L.225-197-1 of the Commercial Code, no Share may be allocated free of charge to an Eligible Person who, at the time of allocation the Share, directly holds more than 10%
of the capital of the Company, or for whom the effect of the award would be to increase his/her participation to more than 10% of the capital of the Company. 

 

	5.	 TERM OF REGULATION 2019-2 

Relying on the authorization and powers granted to it by the General Shareholders’ Meeting on May 24, 2019, the Board of Directors, in its
decision dated December 19, 2019 decided to adopt Regulation 2019-2, which came into effect on December 19, 2019. Unless it is terminated early in accordance with the provisions of Article 11, the 2019-2 Free Share Plan Rules shall remain in force until the expiration of the Vesting Period of the last free Share granted. 
  

	6.	 BONUS SHARE AWARD 

 

	 	(a)	 Decision to award 

At its meeting of December 19, 2019, the Board of Directors decided, within the limit of the authorization granted by the Combined General
Shareholders’ Meeting of May 24, 2019, to grant 100 free shares to the Eligible Persons. 

  
 19 

	 	(b)	 Beneficiaries 

All persons who are Eligible on the Grant Date, i.e. who meet the following two cumulative conditions on that date, are eligible for the grant of Free Shares
under the Plan: 
 (i) they must be an employee of DBV Technologies S.A. under an open-ended or fixed-term contract on December 19, 2019, and 

(ii) provide proof of at least three months’ seniority with DBV Technologies S.A.. 

 

	 	(c)	 Award of Shares and Acceptance by Beneficiaries 

Each Eligible Person will be informed of the Free Share Allocation by a notification letter setting out, in particular, (i) the number of Shares allocated
free of charge to him/her, (ii) the term of the Acquisition Period, (iii) the term of the Retention Period, (iv) the conditions and criteria to be met in order for the award to become definitive at the end of the Acquisition Period,
and (v) any obligation imposed on him/her. A copy of Regulation 2019-2 will be attached to the notification letter. A sample notification letter is set out in an Appendix to Regulation 2019-2. 
 The notification letter will be sent to the Beneficiary by registered mail with acknowledgement of receipt or
delivered by hand to the Beneficiary by the Manager or by any duly authorized person, and the Beneficiary will acknowledge receipt. 
 In the event that the
Beneficiary would like to take up the Free Share Allocation, he/she must make his/her acceptance known to the Company by sending the second copy of the notification of the Free Share Allocation to the Company, addressed to the Manager,
by registered mail with acknowledgement of receipt or by hand, signed by him/her under the notation “Good for acceptance,” within thirty (30) days of receipt of the notification of the Free Share Allocation. 

Acceptance of Regulation 2019-2 by a Beneficiary constitutes acceptance of all of its terms. 

 

	 	(d)	 Number of free shares granted 

The number of Free Shares allocated to each Beneficiary is one hundred (100) according to a uniform allocation of Free Shares among the Beneficiaries;

  

	7.	 CRITERIA AND CONDITIONS OF AWARD 

The allocation of the Shares will take place only at the end of a Vesting Period and subject to a condition of presence of the Beneficiary which was brought to
the attention of the Beneficiaries by individual letters: 
  

	 	(a)	 Vesting Period 

In accordance with the decision of the Combined General Meeting of 24 May 2019, the vesting period is 2 years starting from 19 December 2019. 

 

	 	(b)	 Inalienability of the beneficiary’s rights 

In accordance with Article L.225-197-3 of the French Commercial Code, the
rights resulting from the grent of Free Shares are non-transferable and non-assignable by any means whatsoever until the end of the Vesting Period (except for specific
provisions in the event of the Beneficiary’s death, see below). 

  
 20 

 In the event of the Beneficiary’s death before the expiry of the Vesting Period, his or her heirs may
request the allocation of the Shares within six months from the date of death. In any event, in order to receive the Shares of the deceased Beneficiary, the heirs must undertake to comply with the obligations incumbent upon the Beneficiary under the
Plan. 
  

	 	©	 Conditions for the acquisition of securities : 

The Beneficiary has a definitive right to the Shares resulting from the allocation of the Free Shares only at the end of the Vesting Period, subject to the
specific provisions in the event of disability or death of the Beneficiary described below and that the Beneficiary has retained the status of Eligible throughout the Vesting Period, it being understood that the Beneficiary is deemed to have
retained the status of Eligible in the event of retirement or retirement prior to the Vesting Date. 
 As an exception to the provisions described above,
the definitive allocation of the Shares shall take place before the end of the Vesting Period: 
  

	(i)	 in the event of the death of the Beneficiary during the Acquisition Period, his/her heirs may request the Free
Share Allocation within six (6) months of the death; 

  

	(ii)	 in the event of disability, the Beneficiary may request that the Shares be awarded within six (6) months
of the event that resulted in the disability. 

 In order to be Eligible, the Beneficiary must therefore be linked, during the entire
Vesting Period, to the Company by an employment contract (Presence Condition). 
 It is specified that during the Acquisition Period, the Beneficiaries are
not the owners of the Shares and have no shareholder’s rights. In particular, they do not have the right to dividends, the right to vote, or the right to the information communicated to shareholders attached to the Shares. 

Subject to the specific provisions described above, if the presence condition is not met at the end of the Vesting Period, the Beneficiary loses the Free
Shares, unless the Board of Directors decides otherwise. 
  

	 	(b)	 Delivery of the Shares 

At the end of the Acquisition Period, the Company will, on the condition that the Beneficiary has adhered to the conditions and criteria of acquisition
set out in Article 7 above, transfer to the Beneficiary the number of Shares decided by the Board of Directors. 

  
 21 

 The shares awarded will immediately be treated in the same manner as the existing shares and will carry
immediate dividend rights. 
  

	 	(c)	 No Share Retention Period 

The Beneficiary shall be a shareholder as soon as the Shares are definitively allocated. As soon as they have been definitively allocated, the shares allocated
free of charge may be freely transferred by the Beneficiary, subject to the regulations applicable to companies whose securities are admitted to trading on a regulated market (see in particular Article 13). 

 

	9.	 ADJUSTMENTS 

The Manager will be the only person with authority to decide, where applicable, the conditions on which the number of bonus Shares awarded will be adjusted in
the event of transactions involving the capital of the Company in order to preserve the rights of the Beneficiaries of the said Free Share Allocations. 
  

	10.	 INTERVENING TRANSACTIONS 

 

	(a)	 Take over of control 

In the event of a takeover of control and by derogation from the provisions of Articles 7 and 8 of this regulation, the beneficiaries will remain eligible for
the allocation at the end of the vesting period, even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the takeover and the last day of the vesting period. In this specific case, the shares
will vest with no requirement to wait for the plan’s performance criteria to be met. 
  

	(b)	 Exchange of Shares 

In the event of an exchange of shares resulting from a merger or split carried out in accordance with the regulations in force during the acquisition period,
the provisions of this Article and, in particular, the above-mentioned periods, for the times remaining to run on the date of the exchange, will continue to be applicable to the rights to the award and the shares received in exchange. 

  
 22 

	11.	 AMENDMENT OF REGULATION 2019-2 - MANAGEMENT

  

	 	(a)	 Amendment 

The Manager may, at any time, amend the provisions of, suspend, or terminate Regulation 2019-2, on the condition that
it is done in compliance with the law. 
  

	 	(b)	 Consequences of Amendment or Cancellation 

No amendment, alteration, suspension, or cancellation of Regulation 2019-2 may reduce the rights of a Beneficiary
without his/her agreement, unless such amendment results from a legislative or regulatory provision that has newly come into force or from any other provision that has executory effect and is mandatory for the Company or an Affiliated
Company. 
  

	 	(c)	 Management 

The management of Regulation 2019-2 is assigned to the Manager. However, the Manager reserves the ability to assign the
management of Regulation 2019-2 to any financial institution. The Manager will inform the Beneficiaries by registered letter with acknowledgement of receipt or delivery by hand specifying the name and contact
information of the financial institution chosen by the Manager to handle the management of Regulation 2019-2. 
  

	12.	 TAX AND SOCIAL SECURITY RULES 

The Beneficiary will bear the cost of all taxes and mandatory deductions for which he/she is responsible under the tax regulations in force on the date on
which the taxes or deductions become payable. 
 The Beneficiary is invited to obtain advice about his/her own personal tax situation, in particular in
order to be aware of the tax and social security treatment that will apply to him/her, and the Beneficiary declares that he/she is not in any way relying on any tax or social security advice given by the Company. 

 

	13.	 SPECIFIC RESTRICTIONS AND INFORMATION 

Any person who holds shares of a company must, in general, abstain from transferring them, acquiring new shares, or giving advice concerning those shares if
he/she is in possession of information that could have a significant influence on the market price of the company that has not been made public. Persons who violate those rules may be subject to penal and financial sanctions. Those rules
apply to Eligible Persons who receive Shares. 
 We invite you to refer to the Code of Ethics adopted by the Company that is online on the Intranet.

  
 23 

 Moreover, in accordance with Article
L.225-197-1 I of the Commercial Code, the Shares may not be assigned or transferred after the expiration of the Retention Period: 

 

	 	•	 	 within ten (10) trading sessions preceding and three (3) trading sessions following the date on which
the consolidated accounts or, if none, the annual accounts are made public; 

  

	 	•	 	 within the time between the date on which the corporate bodies of the Company have knowledge of
information that, if it were made public, could have a significant impact on the market price of the Company’s shares, and the date ten (10) trading sessions before the date on which the information is made public.

 A calendar of publications is distributed annually and is accessible online on the Intranet. 

In accordance with the provisions of Article L.621-18-2 of the Monetary and
Financial Code, the transfer of shares by an officer or any person who has, within the Company, (i) the power to make management decisions concerning the Company’s activities and strategy, and (ii) regular access to
privileged information concerning the Company directly or indirectly requires that information be provided to the Autorité des Marchés Financiers [financial markets authority], with a copy to the Company, within the time
allowed by the regulations in force. 
  

	15.	 LIABILITY OF THE COMPANY 

The Company and its Affiliated Companies may not, in any way, be held liable if, for any reason whatsoever not attributable to the Company or its
Affiliated Companies, a Beneficiary was not able to acquire the Shares awarded to him/her. 
  

	16.	 APPLICABLE LAW, JURISDICTION 

Regulation 2019-2 is governed by French law and in particular by the provisions of Articles L.225-197-1 et seq. of the Commercial Code. 
 Any dispute relating to
Regulation 2019-2 will be within the exclusive jurisdiction of the court of competent jurisdiction subject to the jurisdiction of the court of appeal in the place in which the head office of the Company
is located. 
 The Free Share Allocation under Regulation 2019-2 authorizes the Society, at any time, to ask the
Beneficiary to comply with any legislative and regulatory provision governing the Shares. 

*        *        * 

* 

  
 24Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 16, 2020, by and between Cardax, Inc., a
Delaware corporation, with headquarters located at 2800 Woodlawn Drive, Suite 129, Honolulu, HI 96822 (the “Company”),
and __________________ (the “Buyer”).

 

WHEREAS:

 

A.
The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act of 1933, as amended (the “1933 Act”);

 

B.
Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement
a 10% convertible note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal amount of US$250,000.00
(together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance
with the terms thereof, the “Note”), convertible into shares of common stock, $0.001 par value per share, of the Company
(the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Note.

 

C.
The Buyer wishes to purchase, upon the terms and conditions stated in this Agreement, such principal amount of Note as is set
forth immediately below its name on the signature pages hereto; and

 

NOW
THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

 

1.
PURCHASE AND SALE OF NOTE.

 

a.
Purchase of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees
to purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature
pages hereto, subject to the express terms of the Note. In connection with the funding of the Note, the Company shall issue to
Buyer on the Closing Date, as a commitment fee, 5,000 shares of its common stock (the “Commitment Shares”). In connection
with the funding of the Note, the Company shall issue to Buyer on the Closing Date, as a commitment fee, 27,777 shares of its
common stock (the “Returnable Shares”), as further provided in the Note. The Commitment Shares shall be deemed earned
in full as of the Closing Date. The Returnable Shares shall be deemed earned in full as of the Closing Date, provided, however,
the Returnable Shares must be returned to the Company’s treasury if the Note is (i) fully repaid or fully converted and
(ii) satisfied on or prior to the date which is six (6) calendar months following the Issue Date (as defined in the Note), subject
further to the terms and conditions of the Note. The Returnable Shares shall have an appropriate legend stating that such shares
are subject to return to the Company as provided herein.

 

    	 	 	 

    	 

    

 

b.
Form of Payment. On or around the Closing Date (as defined below), the Buyer shall pay the purchase price of $230,000.00
(the “Purchase Price”) for the Note, by wire transfer of immediately available funds, in accordance with the Company’s
written wiring instructions, against delivery of the Note, and (i) the Company shall deliver such duly executed Note on behalf
of the Company, to the Buyer.

 

c.
Closing Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 7 and Section
8 below, the date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall
be 12:00 noon, Eastern Standard Time on or about March 16, 2020, or such other mutually agreed upon time. The closing of the transactions
contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to
by the parties.

 

2.
REPRESENTATIONS AND WARRANTIES OF THE BUYER. The Buyer represents and warrants to the Company that:

 

a.
Investment Purpose. As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon
conversion of or otherwise pursuant to the Note (including, without limitation, such additional shares of Common Stock, if any,
as are issuable (i) at Closing as Commitment Shares and Returnable Shares, (ii) on account of interest on the Note, or (iii) as
a result of the events described in Section 1.3 of the Note, such shares of Common Stock being collectively referred to herein
as the “Conversion Shares” and, collectively with the Note the “Securities”) for its own account and not
with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration
under the 1933 Act; provided, however, that by making the representations herein, the Buyer does not agree to hold any of the
Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance
with or pursuant to a registration statement or an exemption under the 1933 Act.

 

b.
Accredited Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of
Regulation D (an “Accredited Investor”).

 

c.
Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance upon specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility
of the Buyer to acquire the Securities.

 

    	 	 	 

    	 

    

 

d.
Information. The Buyer and its advisors, if any, have been, and for so long as the Note remains outstanding will continue
to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to
the offer and sale of the Securities which have been reasonably requested by the Buyer or its advisors. The Buyer and its advisors,
if any, have been, and for so long as the Note remains outstanding will continue to be, afforded the opportunity to ask questions
of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and
will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure
to the Buyer or such information is subject to appropriate restrictions or limitations so that the Company remains compliant with
law without a requirement to make an announcement or furnish information under Regulation FD. Neither such inquiries nor any other
due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s
right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its
investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a
breach of any of the Company’s representations and warranties made herein.

 

e.
Governmental Review. The Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed upon or made any recommendation or endorsement of the Securities.

 

f.
Transfer or Re-sale. The Buyer understands that (i) the sale or re-sale of the Securities has not been and is not being
registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the
Securities are sold pursuant to an effective registration statement under the 1933 Act, (b) the Buyer shall have delivered to
the Company, at the cost of the Company, an opinion of counsel that shall be in form, substance and scope customary for opinions
of counsel in comparable transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration, which opinion shall be accepted by the Company, (c) the Securities are sold or transferred
to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”))
of the Buyer who agrees to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited
Investor, (d) the Securities are sold pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the
1933 Act (or a successor rule) (“Regulation S”), and the Buyer shall have delivered to the Company, at the cost of
the Company, an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in corporate transactions,
which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only
in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances
in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined
in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder;
and (iii) neither the Company nor any other person is under any obligation to register such Securities under the 1933 Act or any
state securities laws or to comply with the terms and conditions of any exemption thereunder (in each case). Notwithstanding the
foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in connection with a
bona fide margin account or other lending arrangement. In the event that the Company does not accept the opinion of counsel provided
by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144 or Regulation
S, and which shall be in form, substance and scope customary for opinions of counsel in comparable transactions, within three
(3) business days of delivery of the opinion to the Company, it will be considered an Event of Default under Section 3.4 of the
Note.

 

    	 	 	 

    	 

    

 

g.
Legends. The Buyer understands that the Note and, until such time as the Commitment Shares, Returnable Shares and/or Conversion
Shares (as applicable) have been registered under the 1933 Act or may be sold pursuant to Rule 144 or Regulation S without any
restriction as to the number of securities as of a particular date that can then be immediately sold, the Commitment Shares, Returnable
Shares and/or Conversion Shares (as applicable) may bear a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of the certificates for such Securities):

 

“NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER AND
REASONABLY ACCEPTABLE TO THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II)
UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

    	 	 	 

    	 

    

 

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security
upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for
sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation
S without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such
holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable
transactions, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act,
which opinion shall be accepted by the Company so that the sale or transfer is effected. The Buyer agrees to sell all Securities,
including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus
delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided by the Buyer with
respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144 or Regulation S, at the Deadline,
it will be considered an Event of Default pursuant to Section 3.2 of the Note.

 

h.
Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed
and delivered on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in
accordance with its terms.

 

i.
Residency. The Buyer is a resident of the jurisdiction set forth in the preamble and the taxpayer identification information
provided by Buyer is correct.

 

3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Buyer that:

 

a.
Organization and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly
organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power
and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now
owned, leased, used, operated and conducted. The Company and each of its Subsidiaries is duly qualified as a foreign corporation
to do business and is in good standing in every jurisdiction in which its ownership or use of property or the nature of the business
conducted by it makes such qualification necessary except where the failure to be so qualified or in good standing would not have
a Material Adverse Effect. “Material Adverse Effect” means any material adverse effect on the business, operations,
assets, financial condition or prospects of the Company or its Subsidiaries, if any, taken as a whole, or on the transactions
contemplated hereby or by the agreements or instruments to be entered into in connection herewith. “Subsidiaries”
means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly,
in the form of equity or other ownership, a controlling interest.

 

    	 	 	 

    	 

    

 

b.
Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this
Agreement, the Note, and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance
with the terms hereof and thereof, (ii) the execution and delivery of this Agreement and the Note by the Company and the consummation
by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note, the issuance
of the Commitment Shares and Returnable Shares, the reservation and issuance of the Conversion Shares issuable upon conversion
thereof, have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company,
its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company
by its authorized representative, and such authorized representative is the true and official representative with authority to
sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement
constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute, a legal, valid
and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

c.
Capitalization. As of the date hereof, the authorized capital stock of the Company, and shares issued and outstanding,
is as set forth in the Company’s most recent periodic report filed with the SEC, with the exception of (i) shares issued
and outstanding subsequent to the Company’s most recent periodic report filed with the SEC, which are otherwise disclosed
in the SEC Documents or that do not materially change the number of shares issued and outstanding and will be disclosed in the
Company’s next periodic report, (ii) 2,917 shares issued to independent directors in connection with services provided in
the quarter ended December 31, 2019, (iii) 188 shares issued to certain service providers in connection with services provided
in the quarter ended December 31, 2019, and (iv) adjustment to the number of shares issued and outstanding in connection with
the Company’s reverse stock split on January 15, 2020 as disclosed in the SEC Documents. Except as disclosed in the SEC
Documents or in connection with recently issued convertible securities that have substantially similar terms to previously issued
and disclosed convertible securities (in the principal amount of no more than $63,501.15), do not materially change the number
of shares reserved for issuance, and will be disclosed in the Company’s next periodic report, no shares are reserved for
issuance pursuant to the Company’s stock option plans, no shares are reserved for issuance pursuant to securities (other
than the Note) exercisable for, or convertible into, or exchangeable for shares of Common Stock, and 327,230 shares are reserved
for issuance upon conversion of the Note. All of such outstanding shares of capital stock are, or upon issuance will be, duly
authorized, validly issued, fully paid and non-assessable. No shares of capital stock of the Company are subject to preemptive
rights or any other similar rights of the shareholders of the Company or any liens or encumbrances imposed through the actions
or failure to act of the Company. Except as disclosed in the SEC Documents or described herein, as of the effective date of this
Agreement, (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal,
agreements, understandings, claims or other commitments or rights of any character whatsoever relating to, or securities or rights
convertible into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by
which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company
or any of its Subsidiaries, (ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is
obligated to register the sale of any of its or their securities under the 1933 Act and (iii) there are no anti-dilution or price
adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security holders)
that will be triggered by the issuance of the Note, Commitment Shares, Returnable Shares, or the Conversion Shares. The Company
has filed in its SEC Documents true and correct copies of the Company’s Certificate of Incorporation as in effect on the
date hereof (“Certificate of Incorporation”), the Company’s By-laws, as in effect on the date hereof (the “By-laws”),
and the terms of all securities convertible into or exercisable for Common Stock of the Company and the material rights of the
holders thereof in respect thereto, with the exception of recently issued convertible securities that have substantially similar
terms to previously issued and disclosed convertible securities (in the principal amount of no more than $63,501.15), do not materially
change the number of shares reserved for issuance, and will be disclosed in the Company’s next periodic report. The Company
shall provide the Buyer with a written update of this representation signed by the Company’s Chief Executive on behalf of
the Company as of the Closing Date.

 

    	 	 	 

    	 

    

 

d.
Issuance of Shares. The issuance of the Note is duly authorized and, upon issuance in accordance with the terms of this
Agreement, will be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, taxes, liens,
charges and other encumbrances with respect to the issue thereof. The Commitment Shares, Returnable Shares, and, Conversion Shares
are duly authorized, and the Conversion Shares are reserved for issuance and, upon conversion of the Note in accordance with their
respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances
with respect to the issue thereof (except as provided under this Agreement and the Note) and shall not be subject to preemptive
rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

 

e.
Acknowledgment of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common Stock
upon the issuance of the Commitment Shares, Returnable Shares, Conversion Shares upon conversion of the Note. The Company further
acknowledges that its obligation to issue Commitment Shares, Returnable Shares, and Conversion Shares upon conversion of the Note,
in accordance with this Agreement, as well as the Note are absolute and unconditional regardless of the dilutive effect that such
issuances may have on the ownership interests of other shareholders of the Company.

 

    	 	 	 

    	 

    

 

f.
No Conflicts. The execution, delivery and performance of this Agreement and the Note by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Commitment
Shares, Returnable Shares, and, the issuance and reservation for issuance of the Conversion Shares) will not (i) conflict with
or result in a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or
result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could
become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in
a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations
and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company
or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except
for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually
or in the aggregate, have a Material Adverse Effect). Neither the Company nor any of its Subsidiaries is in violation of its Certificate
of Incorporation, By-laws or other organizational documents and neither the Company nor any of its Subsidiaries is in default
(and no event has occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries in default)
under any material contract, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action
that would give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries
is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect.
The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the
Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity. Except as specifically
contemplated by this Agreement and as required under the 1933 Act and any applicable state securities laws, the Company is not
required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency,
regulatory agency, self-regulatory organization or stock market or any third party in order for it to execute, deliver or perform
any of its obligations under this Agreement, the Note in accordance with the terms hereof or thereof or to issue and sell the
Note in accordance with the terms hereof and to issue the Commitment Shares, Returnable Shares and Conversion Shares upon conversion
of the Note. All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant
to the preceding sentence have been obtained or effected on or prior to the date hereof. The Company is not in violation of the
listing requirements of the Over-the-Counter Bulletin Board (the “OTCBB”), the OTCQB or any similar quotation system,
and does not reasonably anticipate that the Common Stock will be delisted by the OTCBB, the OTCQB or any similar quotation system,
in the foreseeable future nor are the Company’s securities “chilled” by DTC. The Company and its Subsidiaries are
unaware of any facts or circumstances which might give rise to any of the foregoing.

 

    	 	 	 

    	 

    

 

g.
SEC Documents; Financial Statements. The Company has timely filed all reports, schedules, forms, statements and other documents
required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended
(the “1934 Act”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial
statements and schedules thereto and documents (other than exhibits to such documents) incorporated by reference therein, being
hereinafter referred to herein as the (“SEC Documents”). The Company has delivered or made available to the Buyer
true and complete copies of the SEC Documents, except for such exhibits and incorporated documents. As of their respective dates,
the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the
SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the
SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. None of the
statements made in any such SEC Documents is, or has been, required to be amended or updated under applicable law (except for
such statements as have been amended or updated in subsequent filings prior the date hereof). As of their respective dates, the
financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have
been prepared in accordance with United States generally accepted accounting principles, consistently applied, during the periods
involved and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries
as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in
the case of unaudited statements, to normal year-end audit adjustments). Except as set forth in the financial statements of the
Company included in the SEC Documents, the Company has no liabilities, contingent or otherwise, other than (i) liabilities incurred
in the ordinary course of business subsequent to September 30, 2019, and (ii) obligations under contracts and commitments incurred
in the ordinary course of business or the issuance or registration of securities as referenced in the SEC Documents that are not
required under generally accepted accounting principles to be reflected in such financial statements, which, individually or in
the aggregate, are not material to the financial condition or operating results of the Company. The Company is subject to the
reporting requirements under Section 15(d) of the 1934 Act. For the avoidance of doubt, filing of the documents required in this
Section 3(g) via the SEC’s Electronic Data Gathering, Analysis, and Retrieval system (“EDGAR”) shall satisfy
all delivery requirements of this Section 3(g).

 

h.
Absence of Certain Changes. Since September 30, 2019, there has been no material adverse change and no material adverse
development in the assets, liabilities, business, properties, operations, financial condition, results of operations, prospects
or 1934 Act reporting status of the Company or any of its Subsidiaries.

 

i
Absence of Litigation. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public
board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries,
threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such,
that could have a Material Adverse Effect. Schedule 3(i) contains a complete list and summary description of any pending or, to
the knowledge of the Company, threatened proceeding against or affecting the Company or any of its Subsidiaries, without regard
to whether it would have a Material Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances
which might give rise to any of the foregoing.

 

    	 	 	 

    	 

    

 

j.
Patents, Copyrights, etc. The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights to
use all patents, patent applications, patent rights, inventions, know-how, trade secrets, trademarks, trademark applications,
service marks, service names, trade names and copyrights (“Intellectual Property”) necessary to enable it to conduct
its business as now operated (and, as presently contemplated to be operated in the future). Except as disclosed in the SEC Documents,
there is no claim or action by any person pertaining to, or proceeding pending, or to the Company’s knowledge threatened,
which challenges the right of the Company or of a Subsidiary with respect to any Intellectual Property necessary to enable it
to conduct its business as now operated (and, as presently contemplated to be operated in the future); to the best of the Company’s
knowledge, the Company’s or its Subsidiaries’ current and intended products, services and processes do not infringe
on any Intellectual Property or other rights held by any person; and the Company is unaware of any facts or circumstances which
might give rise to any of the foregoing. The Company and each of its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of their Intellectual Property.

 

k.
No Materially Adverse Contracts, Etc. Neither the Company nor any of its Subsidiaries is subject to any charter, corporate
or other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers
has or is expected in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party
to any contract or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse
Effect.

 

l.
Tax Status. The Company and each of its Subsidiaries has made or filed all federal, state and foreign income and all other
tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that
the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid
and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown
or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside
on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns,
reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has not executed a waiver with
respect to the statute of limitations relating to the assessment or collection of any foreign, federal, state or local tax. None
of the Company’s tax returns is presently being audited by any taxing authority.

 

    	 	 	 

    	 

    

 

m.
Certain Transactions. Except for any related party transactions disclosed in the SEC Documents and arm’s length transactions
pursuant to which the Company or any of its Subsidiaries makes payments in the ordinary course of business upon terms no less
favorable than the Company or any of its Subsidiaries could obtain from third parties and other than the grant of stock options
disclosed on Schedule 3(c), none of the officers, directors, or employees of the Company is presently a party to any transaction
with the Company or any of its Subsidiaries (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property
to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company,
any corporation, partnership, trust or other entity in which any officer, director, or any such employee has a substantial interest
or is an officer, director, trustee or partner.

 

n.
Disclosure. All information relating to or concerning the Company or any of its Subsidiaries set forth in this Agreement
and provided to the Buyer pursuant to Section 2(d) hereof and otherwise in connection with the transactions contemplated hereby
is true and correct in all material respects and the Company has not omitted to state any material fact necessary in order to
make the statements made herein or therein, in light of the circumstances under which they were made, not misleading. No event
or circumstance has occurred or exists with respect to the Company or any of its Subsidiaries or its or their business, properties,
prospects, operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure or
announcement by the Company but which has not been so publicly announced or disclosed.

 

o.
Acknowledgment Regarding Buyer’ Purchase of Securities. The Company acknowledges and agrees that the Buyer is acting
solely in the capacity of arm’s length purchasers with respect to this Agreement and the transactions contemplated hereby.
The Company further acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by the Buyer or any of
its respective representatives or agents in connection with this Agreement and the transactions contemplated hereby is not advice
or a recommendation and is merely incidental to the Buyer’ purchase of the Securities. The Company further represents to
the Buyer that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of
the Company and its representatives.

 

p.
No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has
directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances
that would require registration under the 1933 Act of the issuance of the Securities to the Buyer. The issuance of the Securities
to the Buyer will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes
of any shareholder approval provisions applicable to the Company or its securities.

 

    	 	 	 

    	 

    

 

q.
No Brokers. The Company hereby represents and warrants that it has not hired, retained or dealt with any broker, finder,
consultant, person, firm or corporation in connection with the negotiation, execution or delivery of this Agreement or the transactions
contemplated hereunder. The Company covenants and agrees that should any claim be made against Buyer for any commission or other
compensation by any broker, finder, person, firm or corporation based upon the Company’s engagement of such person in connection
with this transaction, the Company shall indemnify, defend and hold Buyer harmless from and against any and all damages, expenses
(including attorneys’ fees and disbursements) and liability arising from such claim.

 

r.
Permits; Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations,
licenses, permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and
operate its properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”),
and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of
the Company Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of
the Company Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. Since September 30, 2019, neither the Company nor any of its Subsidiaries
has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices
relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse
Effect.

 

s.
Environmental Matters.

 

(i)
There are, to the Company’s knowledge, with respect to the Company or any of its Subsidiaries or any predecessor of the
Company, no past or present violations of Environmental Laws (as defined below), releases of any material into the environment,
actions, activities, circumstances, conditions, events, incidents, or contractual obligations which may give rise to any common
law environmental liability or any liability under the Comprehensive Environmental Response, Compensation and Liability Act of
1980 or similar federal, state, local or foreign laws and neither the Company nor any of its Subsidiaries has received any notice
with respect to any of the foregoing, nor is any action pending or, to the Company’s knowledge, threatened in connection
with any of the foregoing. The term “Environmental Laws” means all federal, state, local or foreign laws relating
to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened
releases of chemicals, pollutants contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

    	 	 	 

    	 

    

 

(ii)
Other than those that are or were stored, used or disposed of in compliance with applicable law, no Hazardous Materials are contained
on or about any real property currently owned, leased or used by the Company or any of its Subsidiaries, and no Hazardous Materials
were released on or about any real property previously owned, leased or used by the Company or any of its Subsidiaries during
the period the property was owned, leased or used by the Company or any of its Subsidiaries, except in the normal course of the
Company’s or any of its Subsidiaries’ business.

 

(iii)
There are no underground storage tanks on or under any real property owned, leased or used by the Company or any of its Subsidiaries
that are not in compliance with applicable law.

 

t.
Title to Property. Except as disclosed in the SEC Documents the Company and its Subsidiaries have good and marketable title
in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the
business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects or such as would
not have a Material Adverse Effect. Any real property and facilities held under lease by the Company and its Subsidiaries are
held by them under valid, subsisting and enforceable leases with such exceptions as would not have a Material Adverse Effect.

 

u.
Internal Accounting Controls. Except as disclosed in the SEC Documents the Company and each of its Subsidiaries maintain
a system of internal accounting controls sufficient, in the judgment of the Company’s board of directors, to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles
and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or
specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences.

 

v.
Foreign Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee
or other person acting on behalf of the Company or any Subsidiary has, in the course of his actions for, or on behalf of, the
Company, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate
funds; violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or made any
bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or
employee.

 

    	 	 	 

    	 

    

 

w.
[Intentionally Omitted].

 

x.
No Investment Company. The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement
will not be an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment
Company”). The Company is not controlled by an Investment Company.

 

y.
Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses
in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect. Upon written
request the Company will provide to the Buyer true and correct copies of all policies relating to directors’ and officers’
liability coverage, errors and omissions coverage, and commercial general liability coverage.

 

z.
Bad Actor. No officer or director of the Company would be disqualified under Rule 506(d) of the Securities Act as amended
on the basis of being a “bad actor” as that term is established in the September 19, 2013 Small Entity Compliance
Guide published by the SEC.

 

aa.
Shell Status. The Company represents that it is not a “shell” issuer and has never been a “shell”
issuer, or that if it previously has been a “shell” issuer that at least twelve (12) months have passed since the
Company has reported Form 10 type information indicating that it is no longer a “shell” issuer. Further, the Company
will instruct its counsel to either (i) write a 144-3(a)(9) opinion to allow for salability of the Commitment Shares, Returnable
Shares, and/or Conversion Shares or (ii) accept such opinion from Holder’s counsel.

 

bb.
No-Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any
of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in
its 1934 Act filings and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

cc.
Manipulation of Price. The Company has not, and to its knowledge no one acting on its behalf has: (i) taken, directly or
indirectly, any action designed to cause or to result, or that could reasonably be expected to cause or result, in the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold,
bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay
to any person any compensation for soliciting another to purchase any other securities of the Company.

 

    	 	 	 

    	 

    

 

dd.
Sarbanes-Oxley Act. The Company and each Subsidiary is in material compliance with all applicable requirements of the Sarbanes-Oxley
Act of 2002 that are effective as of the date hereof, and all applicable rules and regulations promulgated by the SEC thereunder
that are effective as of the date hereof.

 

ee.
Employee Relations. Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or
employs any member of a union. The Company believes that its and its Subsidiaries’ relations with their respective employees
are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee of the Company
or any of its Subsidiaries has notified the Company or any such Subsidiary that such officer intends to leave the Company or any
such Subsidiary or otherwise terminate such officer’s employment with the Company or any such Subsidiary. To the knowledge
of the Company, no executive officer or other key employee of the Company or any of its Subsidiaries is, or is now expected to
be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement,
non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each
such executive officer or other key employee (as the case may be) does not subject the Company or any of its Subsidiaries to any
liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all federal, state,
local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions
of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect, including without limitation, the accrual of certain wages for
recent pay periods that will be paid upon the closing of the transactions contemplated by this Agreement.

 

ff.
Due Diligence Questionnaire. The Company hereby represents and warrants to Buyer that all of the information furnished
by the Company to Holder on or around the date hereof, pursuant to the due diligence questionnaire form requested by Holder, is
true and correct in all material respects as of the date hereof.

 

gg.
Breach of Representations and Warranties by the Company. The Company agrees that if the Company breaches any of the representations
or warranties set forth in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement,
it will be considered an Event of Default under Section 3.4 of the Note.

 

    	 	 	 

    	 

    

 

4.
COVENANTS.

 

a.
Best Efforts. The parties shall use their commercially reasonable best efforts to satisfy timely each of the conditions
described in Section 7 and 8 of this Agreement.

 

b.
Form D; Blue Sky Laws. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably
determine is necessary to qualify the Securities for sale to the Buyer at the applicable closing pursuant to this Agreement under
applicable securities laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide
evidence of any such action so taken to the Buyer on or prior to the Closing Date.

 

c.
Use of Proceeds. The Company shall use the proceeds from the sale of the Note first for the full repayment of the entire
balance owed under the convertible promissory note issued by the Company on April 18, 2019, in the original principal amount of
$150,000, and second for working capital and other general corporate purposes and shall not, directly or indirectly, use such
proceeds for any loan to or investment in any other corporation, partnership, enterprise or other person (except in connection
with its currently existing direct or indirect Subsidiaries).

 

d.
Notice of Subsequent Transaction. While any amount remains outstanding under the Note, the Company shall, prior to the
closing of any equity financing (including debt with an equity component) with gross proceeds in excess of $500,000.00 but excluding
an underwritten public offering (“Future Offering”), provide written notice to the Buyer describing the proposed Future
Offering, including the terms and conditions thereof. In the event the terms and conditions of a proposed Future Offering are
amended in any respect after delivery of the notice to the Buyer concerning the proposed Future Offering, the Company shall deliver
a new notice to the Buyer describing the amended terms and conditions of the proposed Future Offering. The foregoing sentence
shall apply to successive amendments to the terms and conditions of any proposed Future Offering.

 

e.
Expenses. The Company shall reimburse Buyer for any and all expenses incurred by them in connection with the negotiation,
preparation, execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith
(“Documents”), including, without limitation, reasonable attorneys’ and consultants’ fees and expenses,
transfer agent fees, fees for stock quotation services, fees relating to any amendments or modifications of the Documents or any
consents or waivers of provisions in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of
restructuring the transactions contemplated by the Documents. When possible, the Company must pay these fees directly, including,
but not limited to, any and all wire fees, otherwise the Company must make immediate payment for reimbursement to the Buyer for
all fees and expenses immediately upon written notice by the Buyer or the submission of an invoice by the Buyer. Notwithstanding
the foregoing, the parties agree that all fees and expenses hereunder to be reimbursed by the Company shall not exceed $10,000.

 

    	 	 	 

    	 

    

 

f.
Financial Information. The Company agrees to send or make available the following reports to the Buyer until the Buyer
transfers, assigns, or sells all of the Securities: (i) within ten (10) days after the filing with the SEC, a copy of its Annual
Report on Form 10-K, its Quarterly Reports on Form 10-Q, and any Current Reports on Form 8-K; (ii) within one (1) day after release,
copies of all press releases issued by the Company or any of its Subsidiaries; and (iii) contemporaneously with the making available
or giving to the shareholders of the Company, copies of any notices or other information the Company makes available or gives
to such shareholders. For the avoidance of doubt, filing the documents required in (i) above via EDGAR or releasing any documents
set forth in (ii) above via a recognized wire service shall satisfy the delivery requirements of this Section 4(f).

 

g.
Listing. The Company will, so long as the Buyer owns any of the Securities, maintain the listing and trading of its Common
Stock on the OTCBB, OTCQB, OTCQX, Pink (collectively, “OTC”), or any equivalent replacement quotation system, or the
Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market (collectively, “Nasdaq”), or the
New York Stock Exchange or NYSE American (collectively, “NYSE”), or any equivalent replacement exchange and will comply
in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Financial Industry
Regulatory Authority (“FINRA”) and such exchanges, as applicable. The Company shall promptly provide to the Buyer
copies of any material notices it receives from the OTCBB, OTCQB and any other exchanges or quotation systems on which the Common
Stock is then listed regarding the continued eligibility of the Common Stock for listing on such exchanges and quotation systems.
The Company shall pay any and all fees and expenses in connection with satisfying its obligation under this Section 4(g).

 

h.
Corporate Existence. So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence
and shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or
sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i)
assumes the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith
and (ii) is a publicly traded corporation whose Common Stock is listed for trading on the OTC, Nasdaq, or NYSE.

 

i.
No Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances
that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of
the Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval
provision applicable to the Company or its securities.

 

    	 	 	 

    	 

    

 

j.
Failure to Comply with the 1934 Act. So long as the Buyer beneficially owns the Note, the Company shall comply with the
reporting requirements of the 1934 Act, and the Company shall continue to be subject to the reporting requirements of the 1934
Act.

 

k.
Trading Activities. Neither the Buyer nor its affiliates has an open short position (or other hedging or similar transactions)
in the common stock of the Company and the Buyer agrees that it shall not, and that it will cause its affiliates not to, engage
in any short sales of or hedging transactions with respect to the common stock of the Company.

l.
Restriction on Activities. Commencing as of the date first above written, and until the sooner of the six month anniversary
of the date first written above or payment of the Note in full, or full conversion of the Note, the Company shall not, directly
or indirectly, without the Buyer’s prior written consent, which consent shall not be unreasonably withheld: (a) change the
nature of its business; (b) sell, divest, acquire, change the structure of any material assets other than in the ordinary course
of business; or (c) file any registration statements with the SEC, except for the Company’s registration statement on Form
S-1 No. 333-233281.

 

m.
Legal Counsel Opinions. Upon the request of the Buyer from to time to time, the Company shall be responsible (at its cost)
for promptly supplying to the Company’s transfer agent and the Buyer a customary legal opinion letter of its counsel (the
“Legal Counsel Opinion”) to the effect that the sale of Commitment Shares, Returnable Shares, and Conversion Shares,
by the Buyer or its affiliates, successors and assigns is exempt from the registration requirements of the 1933 Act pursuant to
Rule 144 (provided the requirements of Rule 144 are satisfied and provided the Commitment Shares, Returnable Shares, and Conversion
Shares (as applicable)are not then registered under the 1933 Act for resale pursuant to an effective registration statement).
Should the Company’s legal counsel fail for any reason to issue the Legal Counsel Opinion, the Buyer may (at the Company’s
cost) secure another legal counsel to issue the Legal Counsel Opinion, and the Company will instruct its transfer agent to accept
such opinion.

 

n.
[Intentionally Omitted].

 

o.
Breach of Covenants. The Company agrees that if the Company breaches any of the covenants set forth in this Section 4,
and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of Default
under Section 3.3 of the Note.

 

5.
[Intentionally Omitted].

 

    	 	 	 

    	 

    

 

6.
Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent to issue certificates,
registered in the name of the Buyer or its nominee, for the Commitment Shares, Returnable Shares, and Conversion Shares in such
amounts as specified from time to time by the Buyer to the Company upon conversion of the Note in accordance with the terms thereof
(the “Irrevocable Transfer Agent Instructions”). In the event that the Company proposes to replace its transfer agent,
the Company shall provide, prior to the effective date of such replacement, fully executed Irrevocable Transfer Agent Instructions
in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably
reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to the Company and the Company.
Prior to registration of the Commitment Shares, Returnable Shares, and Conversion Shares under the 1933 Act or the date on which
the Commitment Shares, Returnable Shares, and Conversion Shares may be sold pursuant to Rule 144 without any restriction as to
the number of Securities as of a particular date that can then be immediately sold, all such certificates shall bear the restrictive
legend specified in Section 2(g) of this Agreement. The Company warrants that: (i) no instruction other than the Irrevocable Transfer
Agent Instructions referred to in this Section, and stop transfer instructions to give effect to Section 2(f) hereof (in the case
of the Commitment Shares, Returnable Shares, and Conversion Shares prior to registration of the Commitment Shares, Returnable
Shares, and/or Conversion Shares (as applicable) under the 1933 Act or the date on which the Commitment Shares, Returnable Shares,
and/or, Conversion Shares may be sold pursuant to Rule 144 without any restriction as to the number of Securities as of a particular
date that can then be immediately sold) or Section 1(a) hereof (in the case of the Returnable Shares, which shall be subject to
return to the Company as provided therein), will be given by the Company to its transfer agent and that the Securities shall otherwise
be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Note; (ii)
it will not direct its transfer agent not to transfer or delay, impair, and/or hinder its transfer agent in transferring (or issuing)
(electronically or in certificated form) any certificate for Commitment Shares, Returnable Shares (except that the Returnable
Shares shall have an appropriate legend for so long as such shares are subject to return to the Company), and Conversion Shares
to be issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and this Agreement;
and (iii) it will not fail to remove (or direct its transfer agent not to remove or impair, delay, and/or hinder its transfer
agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate
for any Commitment Shares, Returnable Shares (except that the Returnable Shares shall have an appropriate legend for so long as
such shares are subject to return to the Company), and/or Conversion Shares issued to the Buyer upon conversion of or otherwise
pursuant to the Note as and when required by the Note and this Agreement. Nothing in this Section shall affect in any way the
Buyer’s obligations and agreement set forth in Section 2(g) hereof to comply with all applicable prospectus delivery requirements,
if any, upon re-sale of the Securities. If the Buyer provides the Company, at the cost of the Company, with (i) an opinion of
counsel in form, substance and scope customary for opinions in comparable transactions, to the effect that a public sale or transfer
of such Securities may be made without registration under the 1933 Act and such sale or transfer is effected or (ii) the Buyer
provides reasonable assurances that the Securities can be sold pursuant to Rule 144, the Company shall permit the transfer, and,
in the case of the Commitment Shares, Returnable Shares (except that the Returnable Shares shall have an appropriate legend for
so long as such shares are subject to return to the Company), and Conversion Shares, promptly instruct its transfer agent to issue
one or more certificates, free from restrictive legend, in such name and in such denominations as specified by the Buyer. The
Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer, by vitiating the
intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a
breach of its obligations under this Section may be inadequate and agrees, in the event of a breach or threatened breach by the
Company of the provisions of this Section, that the Buyer shall be entitled, in addition to all other available remedies, to an
injunction restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without
any bond or other security being required.

 

    	 	 	 

    	 

    

 

7.
CONDITIONS PRECEDENT TO THE COMPANY’S OBLIGATION TO SELL. The obligation of the Company hereunder to issue and sell
the Note to the Buyer at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions
thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time
in its sole discretion:

 

a.
The Buyer shall have executed this Agreement and delivered the same to the Company.

 

b.
The Buyer shall have delivered the Purchase Price in accordance with Section 1(b) above.

 

c.
The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and
as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date),
and the Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date.

 

d.
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
Agreement.

 

8.
CONDITIONS PRECEDENT TO THE BUYER’S OBLIGATION TO PURCHASE. The obligation of the Buyer hereunder to purchase the
Note at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided
that these conditions are for the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion:

 

a.
The Company shall have executed this Agreement and delivered the same to the Buyer.

 

    	 	 	 

    	 

    

 

b.
The Company shall have delivered to the Buyer the duly executed Note (in such denominations as the Buyer shall request) and in
accordance with Section 1(b) above.

 

c.
The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to a majority-in-interest of the Buyer, shall
have been delivered to and acknowledged in writing by the Company’s Transfer Agent.

 

d.
The representations and warranties of the Company shall be true and correct in all material respects as of the date when made
and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific
date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.
The Buyer shall have received a certificate or certificates, executed by the chief executive officer of the Company, dated as
of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by the Buyer including,
but not limited to certificates with respect to the Company’s Certificate of Incorporation, By-laws and Board of Directors’
resolutions relating to the transactions contemplated hereby.

 

e.
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
Agreement.

 

f.
No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but
not limited to a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934
Act reporting obligations.

 

g.
The Commitment Shares, Returnable Shares, and Conversion Shares shall have been authorized for quotation on the OTCBB, OTCQB or
any similar quotation system and trading in the Common Stock on the OTCBB, OTCQB or any similar quotation system shall not have
been suspended by the SEC or the OTCBB, OTCQB or any similar quotation system.

 

h.
The Buyer shall have received an officer’s certificate described in Section 3(c) above, dated as of the Closing Date.

 

i.
The Buyer shall have received the amount of Commitment Shares and Returnable Shares, issued as of the Closing Date.

 

    	 	 	 

    	 

    

 

9.
GOVERNING LAW; MISCELLANEOUS.

 

a.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement, the Note or any other agreement, certificate, instrument or document contemplated hereby shall be brought only
in the state courts or federal courts located in the Commonwealth of Massachusetts. The parties to this Agreement hereby irrevocably
waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack
of jurisdiction or venue or based upon forum non conveniens. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE
TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT
OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY
OR THEREBY. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs.
In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party
hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in
connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

b.
Removal of Restrictive Legends. In the event that Buyer has any shares of the Company’s Common Stock bearing any
restrictive legends, and Buyer, through its counsel or other representatives, submits to the Transfer Agent any such shares for
the removal of the restrictive legends thereon in connection with a sale of such shares pursuant to any exemption to the registration
requirements under the Securities Act, and the Company and or its counsel refuses or fails for any reason (except to the extent
that such refusal or failure is based solely on applicable law that would prevent the removal of such restrictive legends) to
render an opinion of counsel or any other documents or certificates required for the removal of the restrictive legends, then
the Company hereby agrees and acknowledges that the Buyer is hereby irrevocably and expressly authorized to have counsel to the
Buyer render any and all opinions and other certificates or instruments which may be required for purposes of removing such restrictive
legends, and the Company hereby irrevocably authorizes and directs the Transfer Agent to, without any further confirmation or
instructions from the Company, issue any such shares without restrictive legends as instructed by the Buyer, and surrender to
a common carrier for overnight delivery to the address as specified by the Buyer, certificates, registered in the name of the
Buyer or its designees, representing the shares of Common Stock to which the Buyer is entitled, without any restrictive legends
and otherwise freely transferable on the books and records of the Company.

 

    	 	 	 

    	 

    

 

c.
Filing Requirements. From the date of this Agreement until the Notes are no longer outstanding, the Company will timely
and voluntarily comply with all reporting requirements that are applicable pursuant to Section 15(d) of the 1934 Act, whether
or not the Company is then subject to such reporting requirements, and comply with all requirements related to any registration
statement filed pursuant to this Agreement. The Company will use reasonable efforts not to take any action or file any document
(whether or not permitted by the 1933 Act or the 1934 Act or the rules thereunder) to terminate or suspend such registration or
to terminate or suspend its reporting and filing obligations under said acts until the Notes are no longer outstanding. The Company
will maintain the quotation or listing of its Common Stock on the OTC, NYSE, or Nasdaq, or any equivalent replacement quotation
system or exchange, whichever of the foregoing is at the time the principal trading market or exchange for the Common Stock (the
“Principal Market”), and will comply in all respects with the Company’s reporting, filing and other obligations
under the bylaws or rules of the Principal Market, as applicable. The Company will provide Buyer with copies of all notices it
receives notifying the Company of the threatened and actual delisting of the Common Stock from any Principal Market. As of the
date of this Agreement and the Closing Date, the OTCQB is the Principal Market. Until the Note is no longer outstanding, the Company
will continue the listing or quotation of the Common Stock on a Principal Market and will comply in all respects with the Company’s
reporting, filing and other obligations under the bylaws or rules of the Principal Market.

 

d.
144 Default. In the event commencing twelve (12) months after the Closing Date and ending twenty-four (24) months thereafter,
provided the Buyer owns any of the Securities, the Buyer is not permitted to resell any of the Commitment Shares, Returnable Shares,
or Conversion Shares without any restrictive legend or if such sales are permitted but subject to volume limitations or further
restrictions on resale as a result of the unavailability to Subscriber of Rule 144(b)(1)(i) under the 1933 Act or any successor
rule (a “144 Default”), for any reason except for Buyers’ status as an Affiliate or “control person”
of the Company, or as a result of a change in current applicable securities laws, then the Company shall pay such Buyer as liquidated
damages and not as a penalty an amount equal to two percent (2%) of the value of the shares (based on the closing sale of the
Common Stock) subject to such 144 Default during the pendency of the 144 Default of each thirty day period thereafter (or portion
thereof); provided, however, that the aggregate amount of any liquidated damages payable by the Company under this Section 9(d)
shall not exceed $25,000.

 

    	 	 	 

    	 

    

 

e.
Usury. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now
or at any time hereafter in force, in connection with any claim, action or proceeding that may be brought by the Buyer in order
to enforce any right or remedy under the Note. Notwithstanding any provision to the contrary contained herein or under the Note,
it is expressly agreed and provided that the total liability of the Company under the Note for payments in the nature of interest
shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum Rate”), and, without limiting
the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated with any other sums
in the nature of interest that the Company may be obligated to pay under the Note or herein exceed such Maximum Rate. It is agreed
that if the maximum contract rate of interest allowed by law and applicable to the Note is increased or decreased by statute or
any official governmental action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will
be the Maximum Rate applicable to the Note from the effective date forward, unless such application is precluded by applicable
law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to the Buyer with respect
to indebtedness evidenced by the Note, such excess shall be applied by the Buyer to the unpaid principal balance of any such indebtedness
or refunded to the Company, the manner of handling such excess to be at the Buyer’s election.

 

f.
Counterparts; Electronic Signatures; Signatures by E-mail or Facsimile. This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party. This Agreement may be executed by electronic
signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as an
original signature. This Agreement, once executed by a party, may be delivered to the other party hereto by e-mail or facsimile
transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

g.
Construction; Headings. This Agreement shall be deemed to be jointly drafted by the Company and the Buyer and shall not
be construed against any person as the drafter hereof. The headings of this Agreement are for convenience of reference only and
shall not form part of, or affect the interpretation of, this Agreement.

 

h.
Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any
law shall not affect the validity or enforceability of any other provision hereof.

 

i.
Entire Agreement; Amendments. This Agreement, the Note, and the instruments referenced herein contain the entire understanding
of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein,
neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No
provision of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest
of the Buyer and the Company.

 

    	 	 	 

    	 

    

 

j.
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder
shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered
or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery, telegram, e-mail, or facsimile, addressed as set forth below or to such other address as
such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be
given hereunder shall be deemed effective (a) upon hand delivery or delivery by e-mail or facsimile, with accurate confirmation
generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during
normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other
than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following
the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing,
whichever shall first occur. The addresses for such communications shall be:

 

If
to the Company:

 

Cardax,
Inc.

2800
Woodlawn Drive, Suite 129

Honolulu,
HI 96822

E-mail:
investors@cardaxpharma.com

 

If
to the Holder:

 

	 
	 
	 
	 

 

Each
party shall provide notice to the other party of any change in address.

 

k.
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and assigns. Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the
prior written consent of the other. Notwithstanding the foregoing, subject to Section 2(f), the Buyer may assign its rights hereunder
to any person that purchases Securities in a private transaction from the Buyer or to any of its “affiliates,” as
that term is defined under the 1934 Act, without the consent of the Company.

 

    	 	 	 

    	 

    

 

l.
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

m.
Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement
shall survive the closing hereunder not withstanding any due diligence investigation conducted by or on behalf of the Buyer. The
Company agrees to indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage
arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and
covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses
as they are incurred.

 

n.
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

o.
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rules of strict construction will be applied against any party.

 

p.
Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Buyer by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the
remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other
available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining,
preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity
of showing economic loss and without any bond or other security being required.

 

q.
Publicity. The Company, and the Buyer shall have the right to review a reasonable period of time before issuance of any
press releases, SEC, OTCQB (or other applicable trading market) or FINRA filings, or any other public statements with respect
to the transactions contemplated hereby; provided, however, that the Company shall be entitled, without the prior approval of
the Buyer, to make any press release or SEC, OTCQB (or other applicable trading market) or FINRA filings with respect to such
transactions as is required by applicable law and regulations (although the Buyer shall be consulted by the Company in connection
with any such press release prior to its release and shall be provided with a copy thereof and be given an opportunity to comment
thereon).

 

    	 	 	 

    	 

    

 

r.
Securities Laws Disclosure. The Company shall comply with applicable securities laws by filing a Current Report on Form
8-K, within four (4) Trading Days following the Closing Date, disclosing all the material terms of the transactions contemplated
hereby, if the Company deems the transactions contemplated hereby to constitute material non- public information.

 

s.
Indemnification. In consideration of the Buyer’s execution and delivery of this Agreement and acquiring the Securities
hereunder, and in addition to all of the Company’s other obligations under this Agreement and the Note, the Company shall
defend, protect, indemnify and hold harmless the Buyer and its stockholders, partners, members, officers, directors, employees
and direct or indirect investors and any of the foregoing persons’ agents or other representatives (including, without limitation,
those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages,
and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification
hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”),
incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation
or warranty made by the Company in this Agreement, the Note, or any other agreement, certificate, instrument or document contemplated
hereby or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in this Agreement, the Note,
or any other agreement, certificate, instrument or document contemplated hereby or thereby, or (c) any cause of action, suit or
claim brought or made against such Indemnitee by a third party (including for these purposes a derivative action brought on behalf
of the Company) and arising out of or resulting from (i) the execution, delivery, performance or enforcement of this Agreement,
the Note, or any other agreement, certificate, instrument or document contemplated hereby or thereby, (ii) any transaction financed
or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (iii) the
status of the Buyer or holder of the Securities as an investor in the Company pursuant to the transactions contemplated by this
Agreement. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall
make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under
applicable law.

 

[signature
page follows]

 

    	 	 	 

    	 

    

 

 

IN
WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above
written.

 

CARDAX,
INC.

 

	By: 	 	 
	Name:
    	 	 
	Title:
    	 	 

 

_____________________

 

	By: 	 	 
	Name:
    	 	 
	Title:
    	 	 

 

AGGREGATE
SUBSCRIPTION AMOUNT:

 

	Aggregate Principal Amount of Note:	 	 	US$250,000.00
	 	 	 	
	Aggregate Purchase Price:	 	 	US$230,000.00

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]